Background: Concomitant quadruple (CQT) or bismuth-containing quadruple ther-
| BACKG ROU N D
Helicobacter pylori gastritis is considered an organic infectious disease that should be treated in all infected subjects. 1 In Spain, H.
pylori approximately infects 50% of the population, 2 but the prevalence is even higher in the northwest of Spain (up to 70%). 3 In recent years, H. pylori eradication rates with conventional triple therapies have fallen to unacceptable levels. 4 Current consensus guidelines highlight the importance of knowing local H. pylori resistance patterns, 1, 2, 5 and the use of therapeutic regimens that can ensure at least a 90% success rate in a particular region is recommended. 1 In this context, the use of empiric triple clarithromycin-containing regimens is discouraged by most recent guidelines if local resistance to clarithromycin is >15%. Concomitant quadruple therapy (CQT) or bismuth-containing quadruple therapy (BQT) is recommended as first-line treatment for H. pylori in areas of high (>15%)
clarithromycin resistance, while only BQT is recommended in areas of high dual clarithromycin and metronidazole resistance (>15%).
5
We have recently reported a high H pylori resistance to clarithromycin (22.4%), but still an acceptable low dual resistance to clarithromycin and metronidazole (9.9%), in the northwest of Spain.
6
In this scenario, we aimed at comparing the eradication rate of CQT and BQT as the first-line H. pylori eradication treatment in clinical practice in our area. Secondary aims included the rate of adverse events and patients' compliance.
| ME THODS

| Study design and patients
An open, prospective, and comparative cross-sectional study comparing the efficacy and safety of CQT and BQT in clinical prac- 
| Procedures
Being this a clinical practice study, patients were not randomized but received CQT or BQT at the discretion of the prescribing physician. Patients with allergy to any of the drugs of one study arm were thus included in the other arm of the study. CQT included omeprazole 20 mg +clarithromycin 500 mg + amoxicillin 1 g + metronidazole 500 mg, all given twice daily for 14 days.
BQT included omeprazole 20 mg twice daily + three capsules of Efficacy of the two eradication regimens was tested at least 6 weeks after completion of treatment by the 13 C-UBT (TAU-KIT®, Isomed, SL, Madrid, Spain). The 13 C-UBT was performed with citric acid and 100 mg of 13 C-urea. A cutoff of delta 13 CO2 <2.0‰ was used to confirm eradication in this study. All patients interrupted any PPI therapy at least 2 weeks before the breath test.
| Outcomes
Primary endpoint of the study was the eradication rate obtained with each eradication treatment. Secondary endpoints included the frequency of adverse events as well as the patients' compliance to the treatment.
| Statistical analysis
Categorical variables are expressed as percentages and continuous variables as mean and standard error of the mean (SEM) and compared by the chi-square and the Student's t test, respectively.
Eradication rates obtained with the two regimens were compared by intention-to-treat (ITT) and per-protocol (PP) analyses, and results are shown as percentages and 95% confidence intervals (95% CI). Statistical significance was established at P < 0.05. All statistical analyses were performed using the statistical software SPSS (version 22; SPSS Inc, Chicago, IL).
The number of patients to be included in the study to show superiority of any of the therapies was unknown for an area of high
H. pylori clarithromycin resistance. Because of that, it was decided
to make an interim analysis after inclusion of the first one hundred patients and to calculate afterward the sample size needed to show superiority of any of the treatments tested.
| Ethical aspects
This study was approved by the Local Ethics Committee. The design and development followed the WMA Helsinki Declaration of 1964, its revisions, and all applicable regulations.
| RE SULTS
One hundred and four consecutive patients were included (67 women, 64.4%, mean age 52.9 years). No invited patient declines to participate. Main indication to test for H. pylori status was uninvestigated dyspepsia (78.8%), followed by peptic ulcer disease (10.6%), first-degree relatives of patients with gastric cancer (7.7%), iron deficiency anemia (1.9%), and idiopathic thrombocytopenic purpura (1%). Fifty patients received CQT while 54 received BQT (Figure 1 ).
Baseline characteristics of patients from CQT and BQT groups were similar, and no difference was observed in terms of age, gender distribution, proportion of smokers, and indication to test for H. pylori infection (Table 1) .
Eradication rate was similar with both therapies at the PP (CQT 97.9%, 95% CI: 93.9-100 vs BQT 96.2%, 95% CI: 90.9-100, P = 0.605) and ITT analyses (CQT 98.0%, 95% CI: 94-100 vs BQT 94.4%, 95%
CI: 88.1-100, P = 0.346). Based on these results, the calculated number of patients needed to demonstrate superiority of one of the therapies is of 5,722 (2,861 in each arm).
Patients' compliance to both treatments was similar (98.0% in CQT group and 98.1% in BQT group, P = 0.956).
The rate of adverse events was similar with CQT (56.0%) and BQT (46.3%) (P = 0.323). Main adverse events included diarrhea (28.0%
in CQT vs 14.9% in BQT; P = 0.257); nausea and vomiting (8.0% in CQT vs 16.7% in BQT; P = 0.357); abdominal pain (6.0% in CQT vs 14.9% in BQT; P = 0.414); and black stools (0% in CQT vs 11.1% in BQT; P = 0.015). Only one patient in each group had to discontinue the treatment due to significant adverse events: one patient in CQT group because of abdominal pain and nausea/vomiting, and one patient in BQT group because of diarrhea and nausea/vomiting (2.0%
CQT vs 1.9% BQT, P = 0.956). The overall outcomes of the study are summarized in Table 2 .
| D ISCUSS I ON
The present study shows that the use of CQT and BQT as first-line eradication treatment against H. pylori is equally effective and safe strategy in an area of high clarithromycin resistance but low dual clarithromycin-metronidazole resistance.
The efficacy of H. pylori eradication therapies depends on multiple factors, but resistance to antibiotics 8 and poor patient compliance 9 are the most relevant ones. In this sense, we have recently published a high H. pylori resistance to clarithromycin (22.4%) but still acceptable low dual resistance to clarithromycin and metronidazole (9.9%) in the northwest of Spain.
6
Poor treatment adherence is secondary to several factors, mainly complex treatment regimens requiring multiple daily doses of different drugs and adverse effects of antimicrobial drugs. 10 The most F I G U R E 1 Flowchart illustrating the cases included in the study a mean ± SEM. b n (%).
TA B L E 1 Baseline characteristics of patients treated with concomitant quadruple therapy (CQT) or Bismuthcontaining quadruple therapy (BQT)
common GI side effects associated with antibiotic therapy include diarrhea, nausea, vomiting, bloating, and abdominal pain that may affect the treatment adherence, 11 with subsequent risk of therapeutic failure and development of antibiotic resistance.
The addition of certain probiotics (different Lactobacillus and
Bifidobacterium strains, S boulardii) may diminish the effects of antibiotics on gut microbiota, 12 improving the adherence to treatment and leading to a higher H pylori eradication rate. Despite its potential benefit, current consensus does not recommend the consistent association of probiotics to eradication treatments. 2, 5 In agreement with it, probiotics were not used in the present study.
Results of the present study confirm that the use of CQT or BQT as first-line eradication treatment against H. pylori in an area of high clarithromycin resistance but low dual resistance is equally effective strategy. Eradication rate obtained by both strategies was similar and clearly above the recommended 90% eradication rate (CQT 98.0% and BQT 94.4% at ITT analysis). These results were even slightly higher than expected according to most recent studies that reported eradication rates ranging from 83% to 95% with CQT [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] and from 80% to 95% with BQT. 25, [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] Since eradication rates of different therapies depend on the H pylori resistance pattern to antibiotics, our results are region specific and only applicable to areas with similar resistance rates to main antibiotics.
In the present study, the frequency of adverse events was similar with both treatments (56% with CQT vs 46.3% with BQT, P = 0.323).
These results were also in accordance with previously reports. 30, 31 Adverse events were generally mild and included diarrhea, nausea and vomiting, and abdominal pain. As expected, the presence of black stools was only reported by patients receiving BQT. This fact should be clearly explained to the patients at the time of prescription to avoid any misinterpretation. Only one patient in each group had to discontinue the treatment in our study due to significant adverse events.
The limited sample size and the nonrandomization of the treatment arms should be mentioned as limitations of the study.
Regarding sample size, inclusion of patients was interrupted once data of the first one hundred patients were analyzed. Since results obtained with both therapeutic regimens were very similar, the possibility of reporting superiority of any of them was considered to be very unlikely. The nonrandomization was part of the study design to report on efficacy in real clinical practice. In that way, patients received one therapy or the other at discretion of the prescribing physician. Baseline characteristics of patients receiving CQT and BQT were similar, and therefore, the impact of a potential patient selection bias is limited. Finally, although it should be mentioned that H. pylori culture was not performed, which could be considered as a limitation of the study, we have very recently evaluated the resistance patterns of H. pylori strains in our area (6) , which most likely remained the same at the time the present study was carried out.
In conclusion, the use of CQT or BQT as first-line treatment against H. pylori in an area with a high resistance rate to clarithromycin but low dual resistance to clarithromycin and metronidazole is safe and effective strategy.
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